Skip to main content

Highly Efficient Blue Light-Emitting Materials Based on Arylamine Substituted DPVBi Derivatives

Buy Article:

$113.00 plus tax (Refund Policy)

Abstract:

A series of arylamine substituted DPVBi derivatives (1–4) were synthesized via the Horner-Wadsworth-Emmons reaction. Their electroluminescent properties were examined by fabricating a multilayer OLED device with the following structure: ITO/DNTPD (40 nm)/NPB (20 nm)/2% DPVBi derivatives (1–4) doped in MADN (20 nm)/Alq3 (40 nm)/Liq (1.0 nm)/Al. All devices showed efficient blue emission. In particular, a high efficiency blue OLED was fabricated using compound 1 as a dopant in the emitting layer. The maximum luminance, luminous efficiency, power efficiency and CIE coordinates of the blue OLED using compound 1 as a dopant were 16110 cd/m2 at 10 V, 10.1 cd/A at 20 mA/cm2, 4.37 lm/W at 20 mA/cm2, and (x = 0.197, y = 0.358) at 8 V, respectively. Moreover, a device using compound 4 as the dopant exhibited efficient deep blue emission with a luminance, luminous efficiency, power efficiency and CIE coordinates of 7005 cd/m2 at 10 V, 6.25 cd/A at 20 mA/cm2, 2.50 lm/W at 20 mA/cm2 and (x = 0.151, y = 0.143) at 8 V, respectively.

Keywords: BLUE OLEDS; DPVBI DERIVATIVES; HORNER-WADSWORTH-EMMONS REACTION

Document Type: Research Article

DOI: https://doi.org/10.1166/jnn.2011.4798

Publication date: 2011-08-01

More about this publication?
  • Journal for Nanoscience and Nanotechnology (JNN) is an international and multidisciplinary peer-reviewed journal with a wide-ranging coverage, consolidating research activities in all areas of nanoscience and nanotechnology into a single and unique reference source. JNN is the first cross-disciplinary journal to publish original full research articles, rapid communications of important new scientific and technological findings, timely state-of-the-art reviews with author's photo and short biography, and current research news encompassing the fundamental and applied research in all disciplines of science, engineering and medicine.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more